The table below shows Autolus Therapeutics plc's cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2021
Q1 2020
Operating cash flow
-$65.32M
-$75.56M
-$40.51M
-$42.42M
-$37.34M
-$24.03M
Capital expenditure
$2.69M
$8.24M
$533.00K
$3.62M
$1.90M
$2.64M
Investing cash flow
$96.15M
-$59.55M
-$533.00K
-$3.62M
-$1.90M
-$2.64M
Dividends paid
-
-
-
AUTL operating cash flow (10-K history)
Autolus Therapeutics plc reported operating cash flow of -$283.57M for fiscal year 2025. That is down 37.5% from -$206.27M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$9.85M (FY 2016) to -$283.57M. Figures come from the company's audited annual reports as filed with the SEC.